Premium
Multidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status
Author(s) -
Delrieu Julien,
Payoux Pierre,
Carrié Isabelle,
Cantet Christelle,
Weiner Michael,
Vellas Bruno,
Andrieu Sandrine
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.07.008
Subject(s) - cognition , medicine , amyloid (mycology) , effects of sleep deprivation on cognitive performance , placebo , alzheimer's disease , psychology , gastroenterology , psychiatry , pathology , disease , alternative medicine
The Multidomain Alzheimer Preventive Trial (MAPT) assessed the efficacy of omega‐3 fatty acid supplementation, a multidomain intervention (MI), or a combination of both on cognition. Impact according to cerebral amyloid status was evaluated by PET scan. Methods Participants were nondemented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. The primary outcome was a change from baseline in 36 months measured with a cognitive composite Z score. Results No effect was observed on cognition in the negative amyloid group (n = 167). In the positive amyloid group (n = 102), we observed a difference of 0.708 and 0.471 in the cognitive composite score between the MI plus omega‐3 fatty acid group, the MI alone group, and the placebo group, respectively. Discussion MI alone or in combination with omega‐3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status. Trial Registration ClinicalTrials.gov Identifier: NCT01513252 .